Financial Analysis: Vireo Growth (VREOD) and Its Peers

Vireo Growth (OTCMKTS:VREOD) is one of 908 public companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Vireo Growth to similar companies based on the strength of its analyst recommendations, dividends, institutional ownership, profitability, valuation, earnings and risk.

Profitability

This table compares Vireo Growth and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vireo Growth	-23.37%	-19.76%	-7.15%
Vireo Growth Competitors	-2,478.03%	-250.55%	-16.90%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Vireo Growth and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vireo Growth	1	0	0	0	1.00
Vireo Growth Competitors	7593	13671	25506	988	2.42

As a group, “Pharmaceuticals” companies have a potential upside of 29.28%. Given Vireo Growth’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Vireo Growth has less favorable growth aspects than its rivals.

Institutional & Insider Ownership

32.9% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.8% of Vireo Growth shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Vireo Growth has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, Vireo Growth’s rivals have a beta of -3.23, meaning that their average stock price is 423% less volatile than the S&P 500.

Valuation & Earnings

This table compares Vireo Growth and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Vireo Growth	$268.77 million	-$68.11 million	-3.02
Vireo Growth Competitors	$16.80 billion	$3.12 billion	511.26

Vireo Growth’s rivals have higher revenue and earnings than Vireo Growth. Vireo Growth is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Vireo Growth rivals beat Vireo Growth on 9 of the 13 factors compared.

Vireo Growth Company Profile

Goodness Growth Holdings, Inc. operates as a cannabis company in the United States. The company cultivates, processes, and distributes medical and adult-use cannabis products. It sells cannabis products through its network of Green Goods and other Goodness Growth branded retail dispensaries and third-party dispensaries in Maryland, Minnesota, and New York. The company was formerly known as Vireo Health International Inc. and changed its name to Goodness Growth Holdings, Inc. in June 2021. Goodness Growth Holdings, Inc. is headquartered in Minneapolis, Minnesota.